Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 425.00
Bid: 425.00
Ask: 434.00
Change: 14.00 (3.41%)
Spread: 9.00 (2.118%)
Open: 411.00
High: 429.00
Low: 411.00
Prev. Close: 411.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

25 Aug 2023 07:00

RNS Number : 3831K
Zotefoams PLC
25 August 2023
 

Zotefoams plc

 

Issue of Equity

 

25 August 2023 - Zotefoams plc (LSE: ZTF) announces that it will allot and issue 225,000 new ordinary shares of five pence each in the capital of the Company ("Ordinary Shares") on 30 August 2023, (the "New Shares").

 

The New Shares, which will rank pari passu with the existing Ordinary Shares in issue, will be allotted and issued to the Zotefoams plc 2007 Employee Benefit Trust (the "EBT") at the par value of five pence each in order to satisfy future exercises of awards under the Group's share incentive schemes.

 

The EBT will thereafter hold a total of 283,135 Ordinary Shares, representing approximately 0.6 percent of the enlarged issued share capital of the Company.

 

Applications have been made to the Financial Conduct Authority (the "FCA") for the admission of the New Shares to the premium listing segment of the Official List of the FCA and to London Stock Exchange plc for admission to trading of the New Shares on its main market for listed securities (together, "Admission"). Admission is expected to become effective at 8.00 a.m. on 30 August 2023.

 

Following Admission, the Company will have 48,846,234 Ordinary Shares in issue. There are no shares held in treasury. Therefore, following Admission the total number of voting rights in the Company will be 48,846,234 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their voting rights interest, or a change to that interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

Zotefoams plc

 

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory (Financial PR & IR)

 

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology, delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA, Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEPPUWURUPWGCC
Date   Source Headline
22nd Jun 20232:20 pmRNSHolding(s) in Company
20th Jun 202310:16 amRNSNotification Of Transactions Of Directors/PDMRs
14th Jun 20237:00 amRNSHolding(s) in Company
13th Jun 20232:55 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
6th Jun 20231:34 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Jun 20238:00 amRNSNike Exclusivity Agreement Extension
24th May 202311:40 amRNSResult of the 2023 Annual General Meeting
24th May 20237:00 amRNSTrading Update and Chair Succession
12th May 202310:42 amRNSNotification Of Transactions Of Directors/PDMRs
27th Apr 20237:00 amRNSHigh-performance foam in medical facility doors
26th Apr 20235:44 pmRNSNotification Of Transactions Of Directors/PDMRs
26th Apr 20233:39 pmRNSNotification Of Transactions Of Directors/PDMRs
24th Apr 20235:50 pmRNSReplacement Notice Transactions Of Directors/PDMRs
24th Apr 20234:42 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Apr 20237:00 amRNS2022 Annual Report and Notice of the 2023 AGM
19th Apr 20234:41 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Apr 20231:18 pmRNSNotification Of Transactions Of Directors/PDMRs
27th Mar 20234:35 pmRNSPrice Monitoring Extension
22nd Mar 20231:30 pmRNSHolding(s) in Company
21st Mar 20234:10 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Mar 20234:09 pmRNSHolding(s) in Company
21st Mar 20237:00 amRNSPreliminary Results
14th Mar 20234:58 pmRNSHolding(s) in Company
14th Mar 20233:09 pmRNSNotification Of Transactions Of Directors/PDMRs
28th Feb 20237:00 amRNSAward of AA ESG Ratings assessment
15th Feb 20237:00 amRNSNotice of Results
14th Feb 20233:34 pmRNSNotification Of Transactions Of Directors/PDMRs
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20237:00 amRNSFull Year Trading Update
17th Jan 20237:00 amRNSChair Succession
12th Jan 202311:18 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20227:00 amRNSTrading Update
13th Dec 20224:03 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Dec 20229:42 amRNSNotification Of Transactions Of Directors/PDMRs
5th Dec 202211:34 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 202211:27 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 20227:00 amRNSAppointment of Joint Broker
9th Nov 20227:00 amRNSAcquisition of the assets and IP of Refour ApS
17th Oct 202211:31 amRNSNotification Of Transactions Of Directors/PDMRs
13th Oct 20227:00 amRNSTrading Update
12th Oct 20224:02 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Oct 20224:41 pmRNSSecond Price Monitoring Extn
11th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Sep 20227:00 amRNSIndependent Life Cycle Assessment of ReZorce
13th Sep 20223:43 pmRNSDirector/PDMR Shareholding
23rd Aug 20224:35 pmRNSPrice Monitoring Extension
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
12th Aug 20221:43 pmRNSDirector/PDMR Shareholding
11th Aug 20223:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.